【摘要】 结核病是由结核分枝杆菌感染引起的全球最为致命的传染病。耐药结核病(MDR-TB、XDR-TB)因治愈率低、治疗周期长，使结核病防治情势日益严峻。开发具有新结构、新作用机制的抗结核药物是治疗耐药结核病的重要手段之一。分枝杆菌膜蛋白3(MmpL3)通过质子动力转运的方式参与分枝菌酸前体海藻糖单分枝菌酸酯(TMM)的跨膜转运，进而在结核杆菌细胞壁的重要组分分枝菌酸的生物合成途径中发挥关键作用。干扰MmpL3的转运功能将破坏结核分枝杆菌的生物活性，因此，MmpL3被认为是当前抗结核药物的重要靶点之一。本文作者对近年来MmpL3抑制剂在抗结核病领域的开发及应用情况进行综述，以期为后续抗结核药物的研究提供有价值的参考。更多还原

【Abstract】 Tuberculosis is the world′s deadliest infectious disease caused by Mycobacterium tuberculosis(Mtb).However, the low cure rate and long treatment cycle of drug-resistant tuberculosis(MDR-TB and XDR-TB) has made tuberculosis prevention and control increasingly severe.Antitubercular drugs with novel structures and mechanisms of action have been proved to be one of the important ways to treat drug-resistant tuberculosis.MmpL3 is involved in the transport of mycolic acid precursor trehalose monomycolates(TMM) through proton-motive force, and then plays a key role in the biosynthetic pathway of mycolic acid, an important component of the cell wall of Mtb.In addition, the down-regulation of expression or knockout of MmpL3 gene will lead to the decrease of the viability or apoptosis of Mtb.Therefore, MmpL3 is one of the important targets for the anti-tuberculosis drugs.In this paper, the developments and applications of MmpL3 inhibitors in the field of tuberculosis treatment in recent years were reviewed, which was expected to provide some valuable references for the research on antitubercular drugs.更多还原